March 20th 2024
The FDA fast-tracked MVR-T3011, an intratumorally injected oncolytic virus, for treating recurrent or metastatic head and neck squamous cell cancer post-platinum chemotherapy and at least 1 prior anti-PD1/PDL1 therapy.
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Phase 2 INSPIRE Trial of IRX-2 Misses EFS End Point in Head and Neck Cancer
July 28th 2022IRX-2 did not demonstrate a statistically significant improvement in event-free survival as neoadjuvant therapy vs standard of care in patients with newly diagnosed, stage II, III, or IVA squamous cell carcinoma of the oral cavity, according to data from the phase 2 INSPIRE trial.
Read More
KEYNOTE-412 Fails to Show EFS Advantage in Unresected Locally Advanced HNSCC
July 20th 2022Patients with unresected locally advanced head and neck squamous cell carcinoma did not show a significant improvement in event-free survival when treated with pembrolizumab and concurrent chemoradiation followed by pembrolizumab maintenance in the phase 3 KEYNOTE-412 study.
Read More
Frontline Tislelizumab Plus Chemo Improves PFS in Recurrent/Metastatic Nasopharyngeal Cancer
June 9th 2022Benefit across a range of survival end points, including progression-free survival, shown with tislelizumab and chemotherapy for patients with recurrent or metastatic nasopharyngeal carcinoma.
Read More
HPV16+ HNSCC Response to PDS0101 Plus Pembrolizumab in VERSATILE-002
June 8th 2022In CPI-naïve, HPV16-positive, CPS-positive patients, PDS0101 plus pembrolizumab exhibits preliminary evidence of clinical benefit in a majority of patients with an acceptable safety profile and allows continued dosing of pembrolizumab.
Read More
FDA Grants Fast Track Status to PDS0101 Plus Pembrolizumab for Recurrent/Metastatic HPV16+ HNSCC
June 2nd 2022A fast track designation has been granted by the FDA to the combination of PDS0101 and pembrolizumab, an investigational regimen for the treatment of patients with recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma.
Read More
Head and Neck Cancer Treatment Evolution Leads the Way for Future Developments
April 29th 2022For Head and Neck Cancer Awareness Month, Robert L. Ferris, MD, PhD, FACS, elaborated on the significant progress in the head and neck cancer space, as well as potentially practice-changing results that will come with emerging agents In an interview with Targeted Oncology™.
Read More
FDA Grants Fast Tracks SQZ-PBMC-HPV for HPV16+ Advanced/Metastatic Solid Tumors
April 28th 2022The FDA has granted fast track designation to SQZ-PBMC-HPV for the treatment of patient with HPV16-positive advanced or metastatic solids tumors, according to an announcement by SQZ Biotechnologies.
Read More
Pepinemab/Pembrolizumab May Be Active in Recurrent/Metastatic Head and Neck Cancer
April 22nd 2022According to results from the phase 1b portion of the study KEYNOTE-B84 study, pepinemab plus pembrolizumab achieved complete responses in 2 of the first 3 patients with head and neck cancers enrolled.
Read More
Tislelizumab Holds PFS Benefit After 15 Months in Recurrent/Metastatic Nasopharyngeal Carcinoma
April 20th 2022Updated results from the RATIONALE-309 study show that tislelizumab continues to prolong PFS extend PFS after the next line of therapy in patients with recurrent or metastatic nasopharyngeal carcinoma.
Read More
High Predictive Value Is Observed for Circulating Tumor Tissue in Oropharyngeal Cancer
April 15th 2022Results from a study evaluating circulating tumor tissue–modified viral (TTMV)–human papillomavirus (HPV) DNA among patients treated for HPV-driven oropharyngeal squamous cell carcinoma is of interest.
Read More
Less Toxicity Observed With Radiotherapy De-Escalation in p16+ Oropharyngeal Squamous Cell Carcinoma
February 25th 2022New data show that de-escalated radiotherapy dose to 54 Gy vs 70 Gy may achieve better measures of toxicity in patients with p16-positive oropharyngeal squamous cell carcinoma.
Read More
Evorpacept Pairs Well With Anticancer Regimens Plus Chemotherapy to Elicit Responses in Solid Tumors
November 10th 2021The novel checkpoint inhibitor, evorpacept induced responses in patients with head and neck squamous cell carcinoma and gastric cancer when used in combination with anticancer therapy and chemotherapy in a phase 1b study.
Read More